Targets › SLC12A3
8 programs from 7 companies in 8 trials: 3 Phase 4, 3 Phase 2, 2 Phase 3; Genitourinary, Cardiovascular, Metabolic and endocrine; next expected readout Dec 2026.
Electroneutral sodium and chloride ion cotransporter, which acts as a key mediator of sodium and chloride reabsorption in kidney distal convoluted tubules. Also acts as a receptor for the pro-inflammatory cytokine IL18, thereby contributing to IL18-induced cytokine production, including IFNG, IL6, IL18 and CCL2 (By similarity). (UniProt, P55017)
Open in Phaseline: the race on SLC12A3, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Chinese University of Hong Kong | Hydrochlorothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 4 | Hypertension | Dec 2026 |
| Icahn School of Medicine at Mount Sinai | Chlorthalidone Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 4 | Kidney Stones | Dec 2027 |
| Lars Rejnmark | Indapamide Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 4 | Hypoparathyroidism Post-surgical | – |
| Johannes Grand | Metolazone Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 3 | Acute Heart Failure | Mar 2028 |
| University Medical Center Groningen | Hydrochlorothiazide Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 3 | ADPKD | Jul 2030 |
| Tanta University | metolazone Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 2 | Acute Decompensated Heart Failure | Feb 2027 |
| Insel Gruppe AG, University Hospital Bern | Chlorthalidone Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 2 | Kidney Stone | Jun 2027 |
| Insel Gruppe AG, University Hospital Bern | Indapamide Thiazide-sensitive sodium-chloride cotransporter inhibitor | SLC12A3 | Phase 2 | Kidney Stone | Jun 2027 |
Kidney Stone (2) ADPKD (1) Kidney Stones (1) Hypertension (1) Acute Decompensated Heart Failure (1) Acute Heart Failure (1) Hypoparathyroidism Post-surgical (1)
small molecule (8)
Insel Gruppe AG, University Hospital Bern (2) University Medical Center Groningen (1) Icahn School of Medicine at Mount Sinai (1) Chinese University of Hong Kong (1) Tanta University (1) Johannes Grand (1) Lars Rejnmark (1)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.